689259-06-1

Basic information

• Product Name: (2-chloro-6-methylpyridin-3-yl)methanol
• Synonyms: (2-chloro-6-methylpyridin-3-yl)methanol;(2-Chloro-6-methyl-3-pyridyl)methanol
• CAS NO: 689259-06-1
• Molecular Formula: C₇H₈ClNO
• Molecular Weight: 157.59752
• Mol File: 689259-06-1.mol

Chemical Properties

• Boiling Point: 279.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.263±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.02±0.10(Predicted)
• CAS DataBase Reference: (2-chloro-6-methylpyridin-3-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-chloro-6-methylpyridin-3-yl)methanol(689259-06-1)
• EPA Substance Registry System: (2-chloro-6-methylpyridin-3-yl)methanol(689259-06-1)

Safety Data

• Hazardous Substances Data: 689259-06-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(2-chloro-6-methylpyridin-3-yl)methanol is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with specific therapeutic properties.
Used in Agrochemical Synthesis:
In the agrochemical industry, (2-chloro-6-methylpyridin-3-yl)methanol serves as an intermediate for the production of various agrochemicals. Its chemical properties make it suitable for the creation of compounds that can be used in crop protection and other agricultural applications.
Used in the Synthesis of Biologically Active Compounds:
(2-chloro-6-methylpyridin-3-yl)methanol has been studied for its potential as a building block in the synthesis of biologically active compounds. Its reactivity and structural features contribute to the development of molecules with significant biological activity, which can be utilized in various research and therapeutic applications.
Proper handling and disposal guidelines should be strictly followed when working with (2-chloro-6-methylpyridin-3-yl)methanol to ensure safety and minimize environmental impact.

Upstream product

• 53277-47-7 2-chloro-6-methylnicotinic acid methyl ester 
• 30529-70-5 2-chloro-6-methyl nicotinic acid 

Relevant articles and documents

SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF

Described herein are compounds of Formula I and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.

TOPICAL FORMULATIONS

Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS

Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to any one of formula (1), (II), (III), (IV), and (V). wherein X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS

Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X1, X2, X3, R1, R2, R2a, R13, Rl3a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagnose blood-based diseases, disorders or conditions.

SMALL MOLECULE INHIBITORS OF NAVL.7 SODIUM CHANNELS FOR THE TREATMENT OF PAIN DISORDERS

The present invention relates to 2 -substituted, 1,1- diarylethanol compounds of formula I, which are inhibitors of the sodium channel NaVl.7, and the use of such compounds in the manufacture of medicaments for the treatment of pain.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.